Eyenovia Announces Co-Branded Validator with Kinetiq 

Rhea-AI Summary

Eyenovia (NASDAQ: EYEN), an ophthalmic technology company, has announced a partnership with Kinetiq to launch a co-branded Hyperliquid validator called 'Kinetiq x Hyperion'. This initiative follows Eyenovia's recent acquisition of 1,040,584.5 HYPE tokens, making it the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol.

The validator will be supported by Pier Two, an institutional staking services provider with SOC 2 Type I and II certifications. This collaboration represents Eyenovia's strategic move into onchain engagement, aiming to contribute to network stability while creating potential value through ecosystem participation.

Positive

• None.

Negative

• Exposure to cryptocurrency market volatility through HYPE token holdings
• Regulatory uncertainty surrounding cryptocurrency operations
• Deviation from core ophthalmic technology business focus

Insights

Blockchain Technology Analyst

Eyenovia's partnership with Kinetiq creates a revenue-generating validator using their substantial HYPE token holdings, representing a strategic blockchain diversification.

Eyenovia's announcement represents a significant evolution in their business strategy, moving beyond their core ophthalmic technology focus into blockchain infrastructure. The company has acquired an impressive 1,040,584.5 HYPE tokens and is now deploying them through a co-branded validator called "Kinetiq x Hyperion" on the Hyperliquid protocol.

This move demonstrates Eyenovia's commitment to generate value from their cryptocurrency holdings rather than simply holding them as treasury assets. By staking their HYPE tokens through a validator, the company can potentially earn staking rewards while contributing to the security and operation of the Hyperliquid network.

The partnership structure is particularly noteworthy: Eyenovia provides the capital (HYPE tokens), Kinetiq brings protocol engineering expertise, and Pier Two delivers the technical infrastructure with institutional-grade security (SOC 2 Type I and II certifications). This three-party arrangement allows Eyenovia to participate in validator economics without needing to develop all technical capabilities in-house.

From an investor perspective, this creates a dual value proposition: Eyenovia now offers exposure both to their traditional ophthalmic business and to potential returns from active participation in the Hyperliquid ecosystem. The company is positioning itself as a "bridge between public markets and the onchain economy" - essentially providing traditional investors with regulated access to cryptocurrency infrastructure returns.

This validator launch signals Eyenovia's intent to actively engage with blockchain projects rather than simply holding digital assets passively, potentially creating new revenue streams tied to network participation rather than solely relying on token price appreciation.

Kinetiq x Hyperion provides a premier liquid staking solution for institutional HYPE holders

LAGUNA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), a pioneer in ophthalmic technologies and the first publicly-listed U.S. company to build a strategic treasury of HYPE, the native token of the Hyperliquid protocol, today announced a co-branded Hyperliquid validator with Kinetiq, a leading liquid staking protocol built natively for the Hyperliquid ecosystem. 

The validator marks a significant step in Eyenovia’s onchain engagement strategy, utilizing its recent acquisition of 1,040,584.5 HYPE to contribute directly to network stability and security. Validator operations are further supported by infrastructure provided by Pier Two, an institutional staking services provider known for its high-performance hybrid cloud and bare metal infrastructure complete with both SOC 2 Type I and Type II certifications. 

“Our collaboration with Kinetiq and Pier Two marks a strategic step in realizing a shared vision for secure, composable, and deeply integrated liquid staking on Hyperliquid,” said Hyunsu Jung, Chief Investment Officer of Eyenovia.

“With Pier Two’s operational expertise and Eyenovia’s landmark treasury acquisition of HYPE, the ‘Kinetiq x Hyperion’ mainnet validator reflects a union of infrastructure, institutional capital, and protocol engineering on what we believe is the future house of all global finance: Hyperliquid,” added Justin Greenberg, Co-Founder and Chief Technology Officer of Kinetiq. 

This validator initiative reflects the first example of Eyenovia’s strategy to engage actively with ecosystem projects, creating the potential for investors to benefit not only from the underlying asset’s performance, but also from value generated through strategic participation, partnerships, and network growth initiatives. This dual approach positions Eyenovia as a unique bridge between public markets and the onchain economy found on Hyperliquid.

About the Hyperliquid Platform and the HYPE Token

Hyperliquid is a layer one blockchain (L1) optimized from the ground up for high frequency, transparent trading. The blockchain includes fully onchain perpetual futures and spot order books, with every order, cancel, trade, and liquidation occurring within 70 millisecond block times. It also hosts the HyperEVM, a general-purpose smart contract platform that, like Ethereum, supports permissionless decentralized financial applications.

HYPE is the native token of Hyperliquid. Staked HYPE in particular provides utility for users via reduced trading fees and increased referral bonuses. Circulating HYPE is autonomously purchased and sequestered by the blockchain itself with the trading fees generated on the network’s order books. As of June 2025, more than 25 million HYPE has been sequestered by this mechanism, and the token has become the 12th-largest cryptocurrency by market capitalization.

About Eyenovia, Inc.
Eyenovia, Inc. is a pioneering digital ophthalmic technology company and the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE. With this dual focus, Eyenovia continues to revolutionize topical eye treatment while providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility.

Eyenovia is also developing its proprietary Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers.

For more information, please visit Eyenovia.com.

Forward Looking Statements
Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our platform technology, the viability of, and risks associated with, our cryptocurrency treasury strategy, the clinical trials that may be necessary in connection with the clearance of the Optejet UFD, and the timing for sales growth of our approved products. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; and our ability to raise additional funds to maintain our business operations and to make payments on our debt obligations as and when necessary.

Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

FAQ

What is the significance of Eyenovia's partnership with Kinetiq?

The partnership establishes a co-branded Hyperliquid validator 'Kinetiq x Hyperion', marking Eyenovia's strategic entry into the Hyperliquid ecosystem and utilizing its HYPE token treasury for network participation.

How many HYPE tokens does Eyenovia (NASDAQ: EYEN) hold?

Eyenovia holds 1,040,584.5 HYPE tokens in its strategic treasury.

Who is providing the infrastructure for Eyenovia's validator operations?

Pier Two, an institutional staking services provider with SOC 2 Type I and II certifications, is providing the infrastructure support for the validator operations.

What makes Eyenovia unique in the cryptocurrency space?

Eyenovia is the first publicly-listed U.S. company to build a strategic treasury of HYPE tokens, positioning itself as a bridge between public markets and the onchain economy on Hyperliquid.

What is the purpose of Eyenovia's validator initiative?

The validator initiative aims to contribute to network stability and security while creating potential value for investors through strategic participation, partnerships, and network growth initiatives in the Hyperliquid ecosystem.